Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diclofenac versus indomethacin versus placebo for prevention of post-ERCP pancreatitis
RBR-10nnzgqhPhase 3Recruiting
- Sponsor
- Faculdade de Medicina de São José do Rio Preto
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Diclofenac arm, Indomethacin arm and Placebo arm (3 arms). Started May 2023; status: recruiting.
02
Drugs
diclofenacindomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on RBR-10nnzgqh.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-10nnzgqh.